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Correspondence 333prolonged unconsciousness, and trauma. In this study,
none of the patients had cardiac symptoms, and we
feel that the elevated cTnI levels may have been due to
causes other than myocardial ischaemia.
False positive cTnI often causes unnecessary
anxiety and over diagnosis of myocardial infarction.
By misrepresenting the implications of cTnI elevation,
this study gives rise to a diagnostic dilemma that
could lead to a wastage of health resources, as well as
inappropriate investigations, which may cause
unnecessary morbidity. An integration of cardiac
biomarkers (CK, CKMB, cTnI), ECG and comprehen-
sive echocardiographic systolic and diastolic function
assessments (wall motion score index),4 and, if
indicated, nuclear medicine scans,5 will better identify
false positive cTnI elevations and will avoid inap-
propriate admissions to coronary care units. Clinical
context must be carefully considered before investi-
gating this group of patients for coronary artery
disease.V.S. Jeganathan*, S. Walker
Royal Hobart Hospital, Australia
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We thank Jeganathan and Walker for their interest
in our study, however, we are concerned that they
have failed to fully understand the pathophysio-
logical and prognostic significance of elevated
levels of cardiac troponin (cTn) I. Their assertion
that the results of our study must be viewed with
caution due to possible ‘false positive cTnI
elevations’ is largely unfounded. Several medical
conditions are associated with elevations in cTnI
level and the underlying mechanism is invariably
myocardial cell death. To illustrate this point, we
will take the examples provided by Jeganathan and
Walker individually:
† Acute coronary syndrome with evidence of raised
cTnI is diagnostic of myocardial injury.
† In the case of myocarditis and pericarditis, it is
active inflammation in or around the heart that
leads to myocardial necrosis and subsequent
elevation of cardiac troponin levels.1
† In moderate to severe pulmonary embolism,
elevated cTnI levels occur in approximately one
in seven patients and are believed to be a
consequence of myocardial damage secondary to
an acute rise of right ventricular afterload and
systemic hypoxemia.2
† In subjects with end stage renal failure (ESRF)
requiring dialysis elevated cardiac troponin levels
are thought to be due to a combination of uraemic
myocarditis and cardiac micro-infarctions as well
as impaired renal excretion.3 Elevations in cTnI,
however, are uncommon as demonstrated by a
large series of 733 subjects with ESRF where only
0.4% were shown to have cTnI levels at a level
diagnostic of myocardial injury.4 None of the
subjects in our study had ESRF.
† The absence of cTnI in foetal and healthy or
diseased adult skeletal muscle5 implies that elev-
ated levels of cTnI do not occur as a result of
rhabdomyolysis. Furthermore, cTnI has been
demonstrated to be a valuable biomarker for the
detection of sub-clinical myocardial damage inEur J Vasc Endovasc Surg Vol 30, September 2005
Correspondence334patients with rhabdomyolysis secondary to
trauma.6
† Whilst we agree that factors such as heterophile
antibodies (HA) can cause interference in immu-
noassays (such as that used to assay cTnI) and thus
produce true false positives, the incidence of
interfering HAs is low.7 Furthermore, the majority
of studies assessing the prognostic significance of
cTnI make no effort to screen and correct for HAs.
Our study demonstrated that up to one third of
patients undergoing bypass surgery for critical lower
limb ischaemia (CLI) sustained peri-operative myo-
cardial injury as manifest by an elevated cTnI.
Regardless of the mechanism of injury, it is clear
that myocardial cell damage occurs in a significant
proportion of these patients and there is abundant
evidence to demonstrate that acute elevations in cTnI
are associated with adverse short and long-term
prognosis in patients undergoing major vascular
surgery.8,9 Jeganathan and Walker are keen to stress
the importance of clinical context when investigating
patients with CLI for coronary artery disease. This
group has such a high incidence of coronary artery
disease that further treatment of those patients
experiencing a cTnI rise seems entirely appropriate.
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//www.sciencedirect.com onEffect of Macrolides on Peripheral Arterial
Disease Depends on Patient Selection and
Adequate Treatment
Vainas et al. investigated a possible effect of a 3-day
azithromycin course on peripheral arterial disease
(PAD) during 2 years. Peripheral arterial compli-
cations were observed in 23% of azithromycin-treated
and 20% of placebo-treated patients. Vainas et al.
concluded that a short-term course of azithromycin
does not influence PAD.1 In contrast, our group
showed that administration of roxithromycin for
28 days prevents progression of PAD in Chlamydia
pneumoniae seropositive men. Limitation of walking
distance to 200 m or less was observed in 20% of
roxithromycin-treated and 65% of placebo-treated
patients. Five invasive revascularizations were
carried out in 20% of roxithromycin-treated patients
compared to 29 interventions in 45% of placebo-
treated patients during 2.7 years.2
The striking difference between the two studies
regarding the effect of macrolides on PAD needs
explanation. Patients were selected differently for the
two studies. Vainas et al. selected patients who either
had an IgA titerO16 (mean 28) EIUs or were C.
pneumoniae seronegative. In contrast, an IgG
titerR1/128 was inclusion criterion of our study,
median C. pneumoniae antibody titers were 1/256
(IgG) and 1/64 (IgA). The percentage of patients
undergoing severe impairment of PAD clearly
differed between the placebo group of Vainas’ study
(20%) and our study (65%). Duration of antibiotic
treatment was different in the two studies. Azithro-
mycin administered for 3 days—though character-
ized by a serum and tissue half life time of several
days—is expected to have a less accentuated
